<DOC>
	<DOC>NCT01274403</DOC>
	<brief_summary>The aim of the study is to compare efficacy and toxicity of melphalan and prednisone versus meplhalan, prednisone and Thalidomide in elderly patients with multiple myeloma or patients with multiple myeloma but not eligible for high dose treatment with stem cells support.</brief_summary>
	<brief_title>A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>newly diagnosed of multiple myeloma. Age &gt; 65 years ECOG &lt;= 3 Written informed consent given at the time of randomization Patients with age &lt;= 65 but not eligible for high dose treatment with stem cells support ECOG &gt; 3 current neoplasm.. contraindications to use thalidomide peripheral neurophaty</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Elderly patients</keyword>
</DOC>